Is Veracyte, Inc. overvalued or undervalued?

As of 7 May 2025, the valuation grade for Veracyte, Inc. has moved from expensive to fair. The company is currently fairly valued, with a P/E ratio of 56, a price to book value of 1.80, and an EV to EBITDA ratio of 35.87. When compared to its peers, Veracyte's P/E of 54.69 is significantly lower than TransMedics Group, Inc. at 94.14, yet higher than Integer Holdings Corp. at 44.32, indicating a competitive positioning within its industry.
Notably, Veracyte's PEG ratio stands at an attractive 0.12, suggesting potential growth relative to its valuation. Despite recent stock performance showing a year-to-date decline of 32.55% compared to a 2.44% gain in the S&P 500, the company's valuation metrics suggest it is not overvalued, especially when considering its fair valuation status in relation to peers.